Pharma giant Lupin announced on Wednesday that the US health agency had given the go-ahead for the marketing of its generic form of Bromfenac Ophthalmic Solution, which is used to treat post-operative inflammation in people who have had cataract surgery.
According to a regulatory filing by Lupin, the US Food and Drug Administration (USFDA) has approved the abbreviated new drug application for bromfenac ophthalmic solution 0.09%.
According to the statement, the item is a generic version of Bausch + Lomb’s Bromday Ophthalmic Solution, 0.09%.
According to the business, the medicine would be produced at Lupin’s Pithampur factory in Madhya Pradesh.
According to Lupin, who cited IQVIA MAT statistics for June, Bromfenac Ophthalmic Solution 0.09 percent had anticipated annual sales worth USD 11 million in the US.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
